mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cgvhd treatment
Published 2 years ago • 524 plays • Length 8:18Download video MP4
Download video MP3
Similar videos
-
2:56
ibrutinib, ruxolitinib & belumosudil for sr-cgvhd
-
1:05
limitations of ibrutinib and ruxolitinib use in cgvhd
-
2:29
ruxolitinib and ibrutinib: the future for gvhd treatment?
-
1:47
the impact of belumosudil in patients with chronic gvhd
-
6:26
how is failure-free survival impacted by belumosudil in cgvhd which has failed prior therapy?
-
1:53
bringing ibrutinib to the frontline of chronic gvhd treatment
-
9:28
david miklos, md, phd: ibrutinib in chronic graft-versus-host disease
-
3:24
understanding the biology of chronic gvhd
-
4:39
robert zeiser | ebmt 2019 | insights into gvhd pathophysiology and strategies to enhance gvl effects
-
3:12
itacitinib clinical trials for chronic and acute gvhd
-
0:53
advances in gvhd management and prophylaxis
-
7:48
ash 2020: highlights for gvhd
-
4:46
reach3 study: should ruxolitinib become soc for steroid-dependent or refractory chronic gvhd?
-
6:44
is axatilimab for cgvhd well tolerated and what does the preliminary response data look like?
-
2:55
splicing machinery dysregulation drives glioblastoma development: oncogenic role of srsf3
-
9:06
jak inhibition in sr cgvhd: reach 3, gravitas-309
-
2:20
itacitinib for the prophylaxis of gvhd and crs in t-cell replete haploidentical pbsct
-
2:26
belimumab for the prophylaxis of chronic gvhd
-
12:11
ecp: looking to the future